Summary & Overview
HCPCS Level II J1429: Injection, golodirsen, 10 mg
HCPCS Level II code J1429 denotes the billed unit for golodirsen injection (10 mg), a specialized injectable therapy used in rare neuromuscular disease management. Nationally, accurate coding for high-cost, specialty injectable drugs such as golodirsen is critical for appropriate payment, utilization tracking, and care coordination across inpatient and outpatient settings. This analysis covers payer coverage patterns and operational benchmarks relevant to commercial and public payers.
Key payers examined include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of coverage considerations and typical billing contexts for J1429, plus a summary of common billing modifiers and service settings. The publication provides clinical context for the drug formulation and typical sites of administration, explains where coding errors commonly occur, and outlines the types of benchmarks and policy updates stakeholders monitor for specialty injectable therapies. Data not available in the input is noted where applicable. The content is intended for billing managers, revenue cycle leaders, pharmacy and therapeutics committees, and policy analysts seeking a concise reference on HCPCS Level II code J1429.
Billing Code Overview
HCPCS Level II code J1429 represents Injection, golodirsen, 10 mg. This code is used to bill for administration of golodirsen, an intravenous or intramuscular injectable therapy delivered in measured 10 mg units.
Service Type: Drug administration (injectable therapy)
Typical Site of Service: Outpatient infusion center, hospital outpatient department, or clinic-based infusion
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a male child or young adult with Duchenne muscular dystrophy (DMD) who is eligible for exon 53 skipping therapy. The patient presents to an outpatient infusion center or hospital outpatient clinic for scheduled administration of golodirsen. The clinical workflow includes verification of diagnosis and eligibility, review of prior authorization and benefit coverage, pre-infusion nursing assessment (vital signs, weight, allergy check), preparation of the J1429 dose (milligrams calculated per pharmacy protocol), intravenous or subcutaneous administration per product labeling, monitoring for infusion-related reactions for the recommended observation period, documentation of lot number and expiration, and post-infusion discharge instructions. Typical site of service is an outpatient infusion center, hospital outpatient department, or specialized neuromuscular clinic supporting ambulatory infusion. Common payer interactions include prior authorization with Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, or Medicare and documentation of medical necessity tied to genetic testing and mutation-specific eligibility.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | When no specific modifier applies to the service |